Scholarlink

<p>This study evaluated the therapeutic effects of a hydroalcoholic extract of <i>Eryngium caucasicum</i> (ECE) on Wistar rats with streptozotocin-induced type 2 diabetes. Forty male rats were divided into four groups (<i>n</i> = 10): healthy controls, diabetic controls, and diabetic groups treated with either 250 or 500&#xa0;mg/kg of ECE for 28 days. GC-MS analysis revealed 12 compounds, with beta-D-glucopyranose (11.6%) and lethene (9.37%) being most prevalent. ECE significantly and dose-dependently reduced fasting blood glucose levels (from 583.1 ± 15.2&#xa0;mg/dL in diabetic controls to 310.5 ± 12.1&#xa0;mg/dL and 208.6 ± 10.4&#xa0;mg/dL at 250 and 500&#xa0;mg/kg, respectively; <i>P</i> &lt; 0.001). In brain tissue, ECE increased glutathione peroxidase (GPx) activity (<i>P</i> &lt; 0.01), decreased malondialdehyde (MDA) levels (<i>P</i> &lt; 0.05), and had minimal effect on total thiols. qRT-PCR analysis of pancreatic tissue showed significant downregulation of Wnt/β-catenin pathway genes (Ctnnb1, Tcf7, Wnt2b; <i>P</i> &lt; 0.05) and upregulation of insulin pathway genes (Ins1 and Glut2; <i>P</i> &lt; 0.01) in ECE-treated diabetic rats. Strong correlations were observed between improved antioxidant levels and glycemic control (e.g., GPx vs. glucose: <i>r</i> = -0.82, <i>P</i> &lt; 0.001), with ROC analysis showing high biomarker potential (AUC &gt; 0.85). These results indicate that ECE reduces hyperglycemia and oxidative stress in type 2 diabetes by boosting antioxidant defenses and modulating Wnt/β-catenin and insulin pathways, highlighting its potential as a phytotherapeutic agent.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic potential of Eryngium caucasicum extract in type 2 diabetes: insights into Wnt/β-catenin and insulin pathway modulation in Wistar rats

  • 期刊论文

  • 发表日期：

    2026年1月5日

查看全文
  • Mehrnaz Ahmadsharbafi,
  • Hadi Habibollahi,
  • Amir Arasteh

摘要

This study evaluated the therapeutic effects of a hydroalcoholic extract of Eryngium caucasicum (ECE) on Wistar rats with streptozotocin-induced type 2 diabetes. Forty male rats were divided into four groups (n = 10): healthy controls, diabetic controls, and diabetic groups treated with either 250 or 500 mg/kg of ECE for 28 days. GC-MS analysis revealed 12 compounds, with beta-D-glucopyranose (11.6%) and lethene (9.37%) being most prevalent. ECE significantly and dose-dependently reduced fasting blood glucose levels (from 583.1 ± 15.2 mg/dL in diabetic controls to 310.5 ± 12.1 mg/dL and 208.6 ± 10.4 mg/dL at 250 and 500 mg/kg, respectively; P < 0.001). In brain tissue, ECE increased glutathione peroxidase (GPx) activity (P < 0.01), decreased malondialdehyde (MDA) levels (P < 0.05), and had minimal effect on total thiols. qRT-PCR analysis of pancreatic tissue showed significant downregulation of Wnt/β-catenin pathway genes (Ctnnb1, Tcf7, Wnt2b; P < 0.05) and upregulation of insulin pathway genes (Ins1 and Glut2; P < 0.01) in ECE-treated diabetic rats. Strong correlations were observed between improved antioxidant levels and glycemic control (e.g., GPx vs. glucose: r = -0.82, P < 0.001), with ROC analysis showing high biomarker potential (AUC > 0.85). These results indicate that ECE reduces hyperglycemia and oxidative stress in type 2 diabetes by boosting antioxidant defenses and modulating Wnt/β-catenin and insulin pathways, highlighting its potential as a phytotherapeutic agent.